Instil is discontinuing its ITIL-168 clinical programs, the DELTA-1 trial in advanced melanoma and the DELTA-2 trial in NSCLC, cervical cancer, and head and neck squamous cell carcinoma. After an analysis of the potential scenarios to restart and complete a registration-enabling cohort in advanced melanoma in the DELTA-1 trial, the Company has decided to prioritize the CoStAR-TIL platform.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TIL:
- Instil Bio treatment of stage IB2 to IV cervical cancer granted orphan status
- Instil Bio reports Q3 EPS (43c), consensus (44c)
- Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Society for Immunotherapy of Cancer to hold a meeting
- Instil Bio announces poster presentations of CoSTAR platform